Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 26 - 50 of 1275 in total

Idecabtagene vicleucel

Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal...
Approved
Matched Description: … myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor …

Valaciclovir

Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It...
Approved
Investigational
Matched Categories: … Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor ... Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor ... Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor …

Belantamab mafodotin

Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufacturer began the process for withdrawal of the...
Approved

Opicapone

Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management...
Approved
Investigational
Matched Description: … (selegiline, rasagiline), a _catechol-O-methyl transferase (COMT)_ inhibitor, or amantadine, or using ... Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase ... A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor …

Ribociclib

Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play...
Approved
Investigational
Matched Description: … Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression …
Matched Categories: … Kinase Inhibitor …

Deucravacitinib

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may...
Approved
Investigational
Matched Description: … Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. …
Matched Categories: … Janus Kinase Inhibitor ... Tyrosine Kinase 2 Inhibitor …

Cilastatin

Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. Since the antibiotic, imipenem, is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent...
Approved
Investigational
Matched Description: … Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of …
Matched Categories: … Renal Dehydropeptidase Inhibitor …

Benserazide

When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the blood and to various extracerebral tissues. This can result in a number of side effects like nausea, vomiting,...
Approved
Investigational
Matched Description: … A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa ... use in Canada and much of Europe, the FDA has approved another similar levodopa/dopa decarboxylase inhibitor …

Gemfibrozil

Gemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. Gemfibrozil was granted FDA approval on 21...
Approved

Everolimus

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and...
Approved
Matched Description: … Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor …
Matched Categories: … Kinase Inhibitor ... mTOR Inhibitor Immunosuppressant …

Metyrosine

An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)
Approved
Matched Description: … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines …
Matched Categories: … Catecholamine Synthesis Inhibitor …

Cemiplimab

Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses. Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment...
Approved
Investigational

Efavirenz

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with...
Approved
Investigational
Matched Description: … Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI …
Matched Categories: … Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor …

Nusinersen

An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S. FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.
Approved
Investigational

Nelarabine

Nelarabine is an antineoplastic agent that is typically used to treat acute T-cell lymphoblastic leukemia, particularly T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), in both adult and pediatric patients whose disease has not responded to or has relapsed following at least two chemotherapy regimens. T-cell acute lymphoblastic...
Approved
Investigational
Matched Categories: … Nucleoside Metabolic Inhibitor …

Evinacumab

Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in...
Approved
Investigational
Matched Description: … [A229278] In February 2021, evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA …
Matched Categories: … Angiopoietin-like 3 Inhibitor …

Trastuzumab

Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal...
Approved
Investigational

Ospemifene

Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
Approved
Investigational

Alverine

Alverine is a smooth muscle relaxant used to relieve cramps or spasms of the stomach and intestines. It is therefore useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain.
Approved
Investigational

Udenafil

Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.
Approved
Investigational
Matched Description: … Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). …

Sacubitril

Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved by the FDA after being given the status of priority review for on July 7, 2015....
Approved
Matched Description: … Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of …
Matched Categories: … Neprilysin Inhibitor …

Filgotinib

Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.[A221451,A221456] The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders. 50-70% of patients with RA are unable to...
Approved
Investigational
Matched Description: … In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. …
Matched Categories: … Janus Kinase Inhibitor …

Entacapone

Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of...
Approved
Investigational
Matched Description: … Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment ... When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased ... levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor …

Rimantadine

An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Approved
Investigational
Matched Description: … An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza …
Matched Categories: … Influenza A M2 Protein Inhibitor …

Netarsudil

A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho...
Approved
Matched Description: … Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel ... A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous ... it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor …
Matched Categories: … Rho Kinase Inhibitor …
Displaying drugs 26 - 50 of 1275 in total